- Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer
- Atossa Therapeutics Announces Full Results from Ph 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
- BriaCell Presents Unprecedented OS Data in Metastatic Breast Cancer
- Incyclix Bio Announces Interim Clinical Data from the Ph 1/2 Trial of INX-315 in Patients with CDK4/6i-resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
- Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Ph 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical TNBC Ph 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22)
- Menarini Group and MEDSIR Present the Phase III Study ADELA
- Menarini Group Presents New and Expanded Data Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
- Lilly’s Imlunestrant Significantly Improved PFS as Monotherapy and in Combination with Verzenio® in Patients with ER+, HER2- Advanced Breast Cancer
- Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
- LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
- Pfizer’s IBRANCE® + SoC Therapies Extends mPFS by Over 15 Months in Ph 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- Results Unveiled for the Ph 3 Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
- TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer